Sotio
SOTIO is dedicated to developing the next generation of potent immunotherapies for cancer patients. The company focuses on advancing safer and more effective immunotherapies through clinical development, with a robust pipeline that includes internally developed and in-licensed candidates for various solid tumor types. As part of PPF Group, SOTIO collaborates with external partners to drive preclinical and clinical development, aiming to rapidly bring projects to clinical trials and commercialization. The company is actively involved in clinical trials for immunocytokines, antibody-drug conjugates, and cell therapies, targeting various cancers including ovarian, lung, and prostate cancers.
Industries
Nr. of Employees
medium (51-250)
Sotio
Prague, Hlavni mesto Praha, Czech Republic, Europe
Products
IL‑15 superagonist immunocytokine candidate
An IL‑15‑based immunocytokine candidate evaluated as monotherapy and in combination with checkpoint inhibitors in multicenter dose‑escalation and expansion studies to activate immune effector cells in the tumor microenvironment.
CAR T‑cell therapy with auxiliary transgenes (GPC3‑targeted program)
Engineered T‑cell therapy program incorporating auxiliary transgenes to enhance function in suppressive tumor microenvironments; evaluated in first‑in‑human dose‑escalation studies with biomarker‑guided patient selection.
Antibody–drug conjugate candidates (preclinical)
Pipeline of ADC candidates for solid tumor targets advanced through preclinical efficacy and safety studies toward IND‑enabling status.
Dendritic cell‑based vaccine programs (ovarian, lung, prostate)
Autologous dendritic cell immunotherapy programs evaluated across multiple randomized Phase II and Phase III clinical studies in ovarian, non‑small cell lung and metastatic prostate cancer, including large multinational enrollment.
IL‑15 superagonist immunocytokine candidate
An IL‑15‑based immunocytokine candidate evaluated as monotherapy and in combination with checkpoint inhibitors in multicenter dose‑escalation and expansion studies to activate immune effector cells in the tumor microenvironment.
CAR T‑cell therapy with auxiliary transgenes (GPC3‑targeted program)
Engineered T‑cell therapy program incorporating auxiliary transgenes to enhance function in suppressive tumor microenvironments; evaluated in first‑in‑human dose‑escalation studies with biomarker‑guided patient selection.
Antibody–drug conjugate candidates (preclinical)
Pipeline of ADC candidates for solid tumor targets advanced through preclinical efficacy and safety studies toward IND‑enabling status.
Dendritic cell‑based vaccine programs (ovarian, lung, prostate)
Autologous dendritic cell immunotherapy programs evaluated across multiple randomized Phase II and Phase III clinical studies in ovarian, non‑small cell lung and metastatic prostate cancer, including large multinational enrollment.
Services
Clinical trial design and execution
Design and run multicenter Phase I/II/III clinical trials including first‑in‑human dose escalation, randomized double‑blind studies, and multi‑country patient enrollment.
Preclinical development and IND‑enabling studies
Preclinical efficacy and safety testing to support candidate selection and regulatory filing packages for oncology candidates.
Business development and partnering
Partnering, in‑licensing, M&A and investment activities to expand and commercialize oncology programs.
Clinical trial design and execution
Design and run multicenter Phase I/II/III clinical trials including first‑in‑human dose escalation, randomized double‑blind studies, and multi‑country patient enrollment.
Preclinical development and IND‑enabling studies
Preclinical efficacy and safety testing to support candidate selection and regulatory filing packages for oncology candidates.
Business development and partnering
Partnering, in‑licensing, M&A and investment activities to expand and commercialize oncology programs.
Expertise Areas
- Immuno‑oncology drug development
- Antibody–drug conjugate discovery and preclinical development
- Adoptive cell therapy engineering with auxiliary transgenes
- Immunocytokine platform development (including IL‑15 and PD‑1 targeting approaches)
Key Technologies
- IL‑15 superagonist molecules
- PD‑1‑targeting immunocytokines
- Cytokine–antibody fusion delivery platforms
- Antibody–drug conjugates